Format

Send to

Choose Destination
Cancer Lett. 2019 Sep 10;459:186-191. doi: 10.1016/j.canlet.2019.114425. Epub 2019 Jun 8.

New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.

Author information

1
Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong; MChem Chemistry and Drug Discovery, University of Sussex, UK.
2
Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
3
Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong. Electronic address: junyu@cuhk.edu.hk.

Abstract

The gastrointestinal tract represents one of the largest interfaces between the host and environmental factors. It contains a vast and complex community of microbes, forming what is collectively known as the microbiota. This gut microbiota plays a pivotal role in the maintenance of health, and 'dysbiosis' of the gut microbiota, commonly considered as perturbation of microbiota diversity and composition, has been associated with intestinal and extra-intestinal diseases, including non-alcoholic fatty liver disease (NAFLD) and its associated hepatocellular carcinoma (NAFLD-HCC). In this review, we highlight microbiota dysbiosis and the microbiota-host interactions that link to the pathogenesis of NAFLD and NAFLD-HCC. We discuss the potential therapeutic implications of the gut microbiota in the progression of NAFLD-HCC.

KEYWORDS:

Gut microbiota; Gut-liver axis; Immunity; Metabolome; NAFLD; NAFLD-HCC

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center